Helius expands range of medicinal cannabis products available to Kiwi patients

Helius Therapeutics, the leading New Zealand-based medicinal cannabis company, is excited to announce the launch of two innovative new products aimed at improving the quality of life for patients seeking alternative treatments. The company proudly introduces a premium NZ-grown medicinal cannabis flower and a convenient oral spray, both launched in November 2024, designed to meet the evolving needs of New Zealand patients.

For the past three years, Helius has been supplying Kiwi patients with high-quality, locally made and grown medicinal cannabis products. Notably, the medicinal cannabis flower is one of the only New Zealand-grown product currently available in the market. It is fully cultivated, dried, cured, processed, and hand-trimmed at Helius’ state-of-the-art facility in Auckland. This commitment to local production ensures that patients receive a high-quality, plant-based treatment option cultivated to the highest standards.

In addition to its success in the New Zealand market, Helius has expanded its operations internationally following recent changes in export regulations in July 2024. The company is now exporting to Australia, Denmark, and South America, building upon its solid foundation in the domestic market.

Medicinal Cannabis Flower: A Natural Treatment Option

Carefully cultivated and processed using advanced agricultural and manufacturing techniques, Helius’ medicinal cannabis flower is rich in cannabinoids and terpenes, offering a full-spectrum experience for patients seeking an alternative to traditional medications. As one of the few New Zealand-grown medicinal cannabis flower available on the market, it exemplifies Helius' dedication to quality and patient care.

“After achieving GMP for flower in 2023, we are thrilled to now be able to deliver on our promise to kiwi patients. Our medicinal cannabis flower is cultivated to the highest standards at our Auckland facility, ensuring a consistent experience for patients,” said Carmen Doran, CEO of Helius Therapeutics. “We are proud to offer the only locally grown product available to Kiwi patients, providing them with the best possible natural treatment option.”

Oral Spray: Aligned with Helius’ Commitment to Addressing Unmet Patient Needs

The oral spray format is a fast-acting, discreet, and easy-to-use option for patients seeking the therapeutic benefits of cannabis. With a precise dosing mechanism, it’s an ideal solution for those who require consistent, controlled use. The launch of the oral spray is aligned with Helius’ broader commitment to addressing unmet patient needs by offering innovative, patient-centric treatment options.

“Our product portfolio is designed with the needs of our patients in mind, providing convenience, accuracy, and a quick onset of relief,” said Carmen Doran. “We understand that many doctors and patients are seeking new ways to manage symptoms, and this product allows access to a safe and effective solution, whether at home or on the go.”

Commitment to Patient-Centric Care

Helius is dedicated to ensuring that all of its products meet the highest standards of safety and quality. The company’s research-driven approach ensures that both the medicinal cannabis flower and oral spray are developed with a focus on patient well-being.

The launch of these two new products aligns with Helius’ broader strategy to expand access and affordability of medicinal cannabis therapies across New Zealand. As demand for alternative treatment options grows, Helius remains committed to meeting the diverse needs of patients while upholding rigorous regulatory standards.